09:54 AM EDT, 06/05/2025 (MT Newswires) -- Estrella Immunopharma ( ESLA ) said Thursday it activated a second site for its phase 1/2 trial assessing EB103 autologous T-cell therapy in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.

The new site at Baylor Scott and White Research Institute in Dallas, Texas, is now open for enrollment, the company said.

The study, which includes a dose escalation phase and an expansion phase, aims to evaluate the safety of EB103 and determine the recommended dose for the phase 2 trial in patients 18 years and older.

Estrella shares were falling 3% in recent trading.

Price: 0.96, Change: -0.03, Percent Change: -3.03